explore -WSS

explore

author：knowledge 2025-10-01 18:45:17 - browse：3474

A medical device to treat below-the-knee chronic limb-threatening ischemia, Esprit BTK resorbable scaffold, is shown consisted of pieces of geometric shapes that lined up into a pipe on a blue background — health tech coverage from STAT — Cardiovascular doctors are optimistic about Abbott’s new below-knee stent that disappears into the blood vessel’s walls over the course of three years. Courtesy Abbott

An Abbott device that failed in heart disease patients is getting a new life in patients with severe vascular disease.

The device is a below-knee stent that widens clogged blood vessels, and then vanishes into the vessel’s walls over the course of three years. It also delivers a drug that prevents scar tissue from forming — a common risk factor with traditional metal stents that further narrow the vessel.

Abbott’s first dissolvable stent, for coronary artery disease, received Food and Drug Administration approval in 2016. But the company voluntarily pulled the product from the market just over a year later due to “low commercial uptake.” The device also received mixed results in clinical trials.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Heart attack and stroke risk calculators need revising
Next article： 5 wounded, 2 critically, in Michigan shopping center shooting

entertainment

WSS

China demands US invite Hong Kong leader to economic meeting, adding to strains over crackdown

Weight loss drug Wegovy cuts risk of heart attacks in milestone trial

Readout Newsletter: What is Casgevy? Does Wegovy hurt muscle?

Weight loss drug Wegovy cuts risk of heart attacks in milestone trial

Ransomware attacks on hospitals: Study outlines patient impact

Hospitals look to new technology to keep health care workers safe

knowledge

explore

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

entertainment

Sports medicine is finally prioritizing gender equality

American TikTok star stuck in Dubai for months following rental car altercation

After affirmative action ruling, medical educators look to 'holistic review'

Snowpack in the West is melting rapidly. Where will all that extra water go?

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Readout Newsletter: Bayer's future, Merck Caraway acquisition, etc

Psychedelics group wrestles with new pharma identity

CRISPR pioneers react to Casgevy, first gene

Medicare proposal to cover medical devices draws a mixed reaction

Weight loss drug Wegovy cuts risk of heart attacks in milestone trial

entertainment

Readout Newsletter: The latest at Gilead, Catalent, and the NIH

House GOP plan to stem drug shortages differs from Democrats’

World's first CRISPR

Judge orders hearing on Trump's motion to disqualify Fulton County DA

Does good food count as health care? Study aims to find out

Sudan conflict brings new atrocities to Darfur as militias kill, rape, burn homes in rampages

leisure time

hotspot

entertainment

hotspot